BioTelemetry, Inc. (BEAT) Expected to Post Earnings of $0.25 Per Share

Wall Street brokerages forecast that BioTelemetry, Inc. (NASDAQ:BEAT) will post $0.25 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for BioTelemetry’s earnings. The highest EPS estimate is $0.30 and the lowest is $0.19. BioTelemetry posted earnings of $0.16 per share in the same quarter last year, which would indicate a positive year over year growth rate of 56.3%. The company is scheduled to announce its next earnings report on Wednesday, May 2nd.

On average, analysts expect that BioTelemetry will report full-year earnings of $1.25 per share for the current year, with EPS estimates ranging from $1.13 to $1.55. For the next year, analysts anticipate that the firm will report earnings of $1.45 per share, with EPS estimates ranging from $1.28 to $1.85. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for BioTelemetry.

How to Become a New Pot Stock Millionaire

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings data on Thursday, February 22nd. The medical research company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The company had revenue of $91.70 million for the quarter, compared to the consensus estimate of $88.33 million. During the same quarter last year, the business posted $0.23 EPS. BioTelemetry’s revenue for the quarter was up 69.8% on a year-over-year basis.

Several equities research analysts recently weighed in on BEAT shares. Dougherty & Co reissued a “buy” rating and set a $41.00 price objective (up previously from $40.00) on shares of BioTelemetry in a report on Friday, February 23rd. BidaskClub raised BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, February 14th. TheStreet downgraded BioTelemetry from a “b-” rating to a “c” rating in a report on Tuesday, March 20th. Finally, Zacks Investment Research raised BioTelemetry from a “strong sell” rating to a “hold” rating in a report on Monday, January 22nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $43.00.

In other BioTelemetry news, insider Fred Broadway sold 54,158 shares of BioTelemetry stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total transaction of $1,850,578.86. Following the transaction, the insider now directly owns 64,880 shares of the company’s stock, valued at approximately $2,216,949.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.30% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC bought a new position in shares of BioTelemetry in the 4th quarter worth about $12,910,000. MetLife Investment Advisors LLC bought a new position in shares of BioTelemetry in the 4th quarter worth about $397,000. Lyon Street Capital LLC raised its position in shares of BioTelemetry by 2,368.9% in the 4th quarter. Lyon Street Capital LLC now owns 379,029 shares of the medical research company’s stock worth $11,333,000 after acquiring an additional 363,677 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of BioTelemetry by 8,866.8% in the 4th quarter. Macquarie Group Ltd. now owns 756,263 shares of the medical research company’s stock worth $22,612,000 after acquiring an additional 747,829 shares in the last quarter. Finally, Vident Investment Advisory LLC bought a new position in shares of BioTelemetry in the 4th quarter worth about $612,000. 87.64% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ BEAT traded down $0.30 during mid-day trading on Monday, hitting $30.75. 235,743 shares of the stock traded hands, compared to its average volume of 423,513. The company has a quick ratio of 1.66, a current ratio of 1.77 and a debt-to-equity ratio of 0.80. BioTelemetry has a twelve month low of $23.30 and a twelve month high of $39.20. The company has a market cap of $1,016.15, a price-to-earnings ratio of 31.70, a price-to-earnings-growth ratio of 1.56 and a beta of 0.86.

WARNING: This report was originally reported by WKRB News and is the property of of WKRB News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.wkrb13.com/2018/04/02/biotelemetry-inc-beat-expected-to-post-earnings-of-0-25-per-share.html.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply